BR112022014616A2 - Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca - Google Patents

Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca

Info

Publication number
BR112022014616A2
BR112022014616A2 BR112022014616A BR112022014616A BR112022014616A2 BR 112022014616 A2 BR112022014616 A2 BR 112022014616A2 BR 112022014616 A BR112022014616 A BR 112022014616A BR 112022014616 A BR112022014616 A BR 112022014616A BR 112022014616 A2 BR112022014616 A2 BR 112022014616A2
Authority
BR
Brazil
Prior art keywords
pacap
constructs
treatment
peptide
adenylate cyclase
Prior art date
Application number
BR112022014616A
Other languages
English (en)
Inventor
Yi Wang Chang
Lin Feng
Ding Shuang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR112022014616A2 publication Critical patent/BR112022014616A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

IMUNÓGENOS PEPTÍDICOS DE ALVEJAMENTO DE PEPTÍDEO ATIVADOR DE ADENILATO CICLASE PITUITÁRIA (PACAP) E FORMULAÇÕES DO MESMO PARA PREVENÇÃO E TRATAMENTO DE ENXAQUECA. A presente divulgação se refere a construtos de imunógeno peptídico de alvejamento de porções de polipeptídeo ativador de adenilato ciclase pituitária (PACAP), composições que contêm os construtos, anticorpos induzidos pelos construtos e métodos de fabricação e uso dos construtos e composições dos mesmos. Os construtos de imunógeno peptídico divulgados têm mais de cerca de 20 aminoácidos e contêm (a) um epítopo de célula B que tem cerca de mais de cerca de 9 resíduos de aminoácidos contíguos das regiões de ativação ou ligação ao receptor de PACAP da proteína PACAP de comprimento total; (b) um epítopo Th heterólogo e (c) um espaçador heterólogo opcional. Os construtos de imunógeno peptídico PACAP divulgados estimulam a geração de anticorpos altamente específicos direcionados ao PACAP para a prevenção e/ou tratamento de enxaqueca.
BR112022014616A 2020-01-23 2021-01-22 Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca BR112022014616A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964953P 2020-01-23 2020-01-23
PCT/US2021/014640 WO2021150910A1 (en) 2020-01-23 2021-01-22 Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine

Publications (1)

Publication Number Publication Date
BR112022014616A2 true BR112022014616A2 (pt) 2022-12-13

Family

ID=76992767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014616A BR112022014616A2 (pt) 2020-01-23 2021-01-22 Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca

Country Status (10)

Country Link
US (1) US20230146694A1 (pt)
EP (1) EP4093756A4 (pt)
JP (1) JP2023511421A (pt)
KR (1) KR20220131951A (pt)
AU (1) AU2021210391A1 (pt)
BR (1) BR112022014616A2 (pt)
CA (1) CA3168991A1 (pt)
MX (1) MX2022009144A (pt)
TW (1) TWI823051B (pt)
WO (1) WO2021150910A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037321A (en) * 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
WO2016168757A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2017106578A1 (en) * 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
WO2019084488A1 (en) * 2017-10-27 2019-05-02 United Neuroscience IMMUNOGENIC CONSTRUCTS OF PEPTIDE TAU
JP7239203B2 (ja) * 2017-12-31 2023-03-14 ユナイテッド・バイオメディカル・インコーポレーテッド ＩｇＥ媒介型アレルギー性疾患治療のための、膜結合型ＩｇＥを標的とするペプチド免疫原及びそれらの製剤
SG11202107046YA (en) * 2018-12-31 2021-07-29 United Neuroscience Ltd Peptide immunogens targeting calcitonin gene-related peptide (cgrp) and formulations thereof for prevention and treatment of migraine

Also Published As

Publication number Publication date
KR20220131951A (ko) 2022-09-29
TW202140526A (zh) 2021-11-01
WO2021150910A1 (en) 2021-07-29
JP2023511421A (ja) 2023-03-17
AU2021210391A1 (en) 2022-09-15
MX2022009144A (es) 2022-08-22
TWI823051B (zh) 2023-11-21
US20230146694A1 (en) 2023-05-11
EP4093756A4 (en) 2024-06-12
CA3168991A1 (en) 2021-07-29
EP4093756A1 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
DE69918146T2 (de) Verfahren zur therapeutischen impfung
Albarracin et al. Identification of a major prolactin-regulated protein as 20 alpha-hydroxysteroid dehydrogenase: coordinate regulation of its activity, protein content, and messenger ribonucleic acid expression
ES2627882T3 (es) Control inmunogénico de tumores y células tumorales
HU214453B (hu) Eljárás húsok organoleptikus minőségének javítására
CN106687129B (zh) 注射用药物组合物
BR112021012906A2 (pt) Imunógenos de peptídeo que têm como alvo peptídeo relacionado ao gene da calcitonina (cgrp) e formulações dos mesmos para prevenção e tratamento de enxaqueca
Brumeanu et al. Immunogenicity of a contiguous TB synthetic epitope of the A/PR/8/34 influenza virus
Helting et al. Analysis of the immune response to papain digestion products of tetanus toxin
BR112022014616A2 (pt) Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca
RU2011100104A (ru) Слитый белок дефектная хлорамфеникол ацетилтрансфераза (сат)-соматостатин и его применения
HUT52787A (en) Process for production of biologically active peptides
CN107073086B (zh) 免疫性lhrh组合物及其在猪只中的应用
PH12020550239A1 (en) Periodontitis vaccine and related compositions and methods of use
RU2660566C2 (ru) Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген
MX2020006976A (es) Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos.
JPH01301696A (ja) ペプチド構造体、それらを含む免疫原及び妊性の調節へのそれらの使用
JPH10330256A (ja) グリチルレチン酸化合物含有ｈｓｐ４７合成抑制剤
Gupta et al. Development of a novel recombinant LHRH fusion protein for therapy of androgen and estrogen dependent cancers
JP4384054B2 (ja) 新生物形成の処置のための増殖調節因子及びホルモンの組合せ
Ibañez et al. Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains
Marchis-Mouren et al. HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism
BR112022015863A2 (pt) Imunógenos de peptídeo de alvejamento de polipeptídeo amiloide da ilhota (iapp) para prevenção e tratamento de distúrbios relacionados a iapp agregado
EP4226947A1 (en) Covalent conjugates of the sars-cov-2 receptor-binding domain and a carrier protein and vaccine compositions that contain them
TWI653049B (zh) 合成多肽、包含該合成多肽之疫苗組合物及其用途
EP4183417A1 (en) An immunotherapeutic for prostate cancer treatment